Skip to main content

Aggressive, Early Disease-Modifying Therapy May Slow MS Progression

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 27, 2024.

By Lori Solomon HealthDay Reporter

FRIDAY, Sept. 27, 2024 -- Reducing or preventing paramagnetic rim lesions (PRLs) could significantly slow multiple sclerosis (MS) progression, according to a study presented at the annual meeting of the American Neurological Association, held Sept. 14 to 17 in Orlando, Florida.

Jack Reeves, Ph.D., from State University of New York at Buffalo, and colleagues assessed the relationship between new PRL appearance, disappearance, or persistence over five years and the prevalence of confirmed disability progression (CDP) and progression independent of relapse activity (PIRA). The analysis included 93 people with MS who had 3T magnetic resonance imaging at baseline.

The researchers found that significantly increased odds of CDP were associated with the number of persisting PRLs (exp(β) = 1.24). There was also a significant association between increased odds of PIRA occurrence and number of persisting PRLs (exp(β) = 1.35) and the presence of newly appearing PRLs (exp(β) = 8.68). Reducing the number of persisting PRLs to zero in people with MS and at least one baseline PRL (PRL+) would result in an estimated 45.6 percent relative reduction in five-year PIRA prevalence (26.1 to 14.2 percent of PRL+) and a 27.1 percent relative reduction in five-year CDP prevalence (30.4 to 22.2 percent of PRL+). Completely preventing new PRLs in the whole cohort would result in an estimated 14.0 percent relative reduction in five-year PIRA prevalence (22.9 to 19.7 percent).

"Our data suggest that development of novel disease-modifying therapies that efficaciously target ongoing chronic active inflammation would significantly reduce the burden of clinical disease progression in the MS population," the authors write.

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted September 2024

Read this next

Common Medications Tied to Older Age at Onset of Parkinson Disease

FRIDAY, April 25, 2025 -- Multiple common medications are associated with a considerable delay of Parkinson disease (PD) symptom onset, according to a study published online March...

Proinflammatory Diet Tied to Higher Risk for Chronic Kidney Disease

WEDNESDAY, April 23, 2025 -- Individuals who eat a proinflammatory diet have a higher likelihood of chronic kidney disease, according to a review published online April 16 in...

AAN: Tolebrutinib Slows Disability in Nonrelapsing Secondary Progressive MS

WEDNESDAY, April 9, 2025 -- Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation within the central nervous...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.